| Dear Voornaam
Next year’s Data-driven cancer research conference is shaping up to be a must attend event.
Corinne Faivre-Finn (University of Manchester) and Mark Lawler (Queen’s University Belfast) will both deliver keynote addresses, alongside a stellar speaker line-up covering topics from data-enabled research and trials to leveraging data and AI tools for patient and public benefit.
To explore the full agenda, visit our website and follow along #CRUKDataConf24 on social media for the latest news and speakers.
Register now to join the conversation in Manchester on 27-28 February 2024. |
|
|---|
|
|---|
|
|
Funding & Research Opportunities |
|
|---|
|
|---|
| | | Applications accepted all-year round |
|
|---|
|
|---|
| | | Applications accepted all-year round |
|
|---|
|
|---|
| | | Applications accepted all-year round |
|
|---|
|
|---|
|
|
FUNDING FOR EARLY DETECTION AND DIAGNOSIS RESEARCH PROJECTS Calling cancer early detection and diagnosis researchers. Our Early Detection and Diagnosis Project Awards fund science to drive transformational change in how and when early cancers and pre-cancerous states are diagnosed.
Apply before 14 December to receive up to £500k funding.
|
|
|---|
|
|---|
|
|
 $6.5M FUNDING FOR PRECISION BREAST CANCER RESEARCH IN CAMBRIDGE Congratulations to Jean Abraham (University of Cambridge) and Greg Hannon (Cancer Research UK Cambridge Institute) who have been awarded $6.5m to develop tools to help predict the best treatment options for people with high-risk breast cancer of multiple sub-types.
At present, only a fraction of the data collected from patients is used to determine treatment options due to its format and where it’s stored.
The funding from the US Department of Defence, Department of the Navy and Office of Naval Research is managed via an initiative called the congressionally directed medical research programs. It will allow the team, led by Abraham, to create an integrated data platform using machine learning and AI for data analysis. Hannon’s lab will analyse individual cells in the biopsy samples. The project will help understand why some cancers respond to treatment and others do not, and why some cancers recur and spread while others do not. |
|
|---|
|  GENERATIVE AI AND RESEARCH INTEGRITY How can researchers keep up with the fast-changing landscape of generative AI and its unique challenges?
In our latest blog from our series on research integrity, Andrew Porter (Cancer Research UK Manchester Institute) dives into the complexities of generative AI and its impact on research integrity.
Andrew discusses the challenges of generative AI that researchers must address, drawing on principles underpinning good research integrity as a framework for thinking about generative AI, and talks through tips on how we might keep up with changing regulations, guidance and policy. |
|
|---|
|
|---|
|
|
TRACTABLE METABOLIC VULNERABILITY IN BREAST CANCER Peter Kreuzaler, Mariia Yuneva and colleagues have found that pantothenic acid (also known as vitamin B5) supports Myc oncogenic metabolism and tumour progression in breast cancer.
They used correlative mass spectrometry imaging to show that pantothenic acid is a key metabolite associated with Myc-high areas within both human and murine mammary tumours. It is an essential source of coenzyme A and thus supports an increased uptake of nutrients into the Krebs cycle in Myc-high tumour cells.
These findings published in Nature Metabolism established the availability of vitamins and cofactors as a potential block in tumour progression, which may be able to be exploited therapeutically.
The research, undertaken by members of the Cancer Grand Challenges Rosetta team, showed that a spatial understanding of local metabolism enables the identification of clinically relevant and tractable metabolic targets. |
|
|---|
|
|---|
|
|
 FIND AN INDUSTRY MENTOR Find your industry mentors with Broadening Horizons to develop your health-related innovative research.
The entrepreneurial programme offers in-person and digital opportunities to learn, network and forge new relationships in the health sector. You will hear from world-leading speakers and take part in mentoring trainings to develop the skills and mindset you need for clinical translation.
The programme is funded by our innovation arm, Cancer Research Horizons in partnership with Wellcome and Moving Ahead. |
|
|---|
|  BRAIN TUMOUR CONFERENCE 2024 - SAVE THE DATE Our Brain Tumour Conference is returning to London on 24–26 September 2024, bringing together international experts in brain tumour research and other disciplines to showcase new discoveries and spark opportunities for collaboration.
The scientific committee, Richard Gilbertson (Cancer Research UK Cambridge Institute), Adrienne Boire (Memorial Sloan Kettering Cancer Centre), Nada Jabado (McGill University) and Steven Pollard (University of Edinburgh) are curating a packed agenda of scientific sessions, networking and panel discussions.
Register your interest to be the first to hear about when registration opens and the speaker line-up.
|
|
|---|
|
|---|
|
|
| | | London, UK 14 November 2023 |
|
|---|
|
|---|
| | | Edinburgh, UK 14 November 2023 |
|
|---|
|
|---|
| | | London, UK 21 November 2023 |
|
|---|
|
|---|
| | | London, UK 29 November 2023 |
|
|---|
|
|---|
| | | London, UK 17 January 2024 |
|
|---|
|
|---|
| | | Manchester, UK 27 February 2024 |
|
|---|
|
|---|
|
|
WHAT DID YOU THINK OF THIS EMAIL? We're always looking for ways to improve. Please give us your feedback by clicking below and leaving a comment. |
|
|---|
|
|---|
|
|
| Been forwarded this email?
Subscribe to our newsletter to stay up-to-date. |
|---|
| |
|---|
|
|
|
